BOLETÍN BIBLIOGRÁFICO
DE INMUNOTERAPIA
Artículo destacado – Agosto 2022
1
Un futuro prometedor para los alérgicos al gato
REGN1908/1909 prevented cat allergen-induced early asthmatic responses in an environmental exposure unit
de Blay FJ, Gherasim A, Domis N, Meier P, Shawki F, Wang CQ, Orengo JM, DeVeaux M, Ramesh D, Jalbert JJ, Kamal MA, Abdallah H, Dingman R, Perlee L, Weinreich DM, Herman G, Yancopoulos GD, O'Brien MP
J Allergy Clin Immunol. 2022 Aug 4:S0091-6749(22)00984-8. PMID: 35934082
BACKGROUND
The dominant allergen in cat dander, Felis domesticus allergen 1 (Fel d 1), is a persistent trigger for allergic rhinitis and asthma symptoms.
OBJECTIVE
Evaluate the efficacy of Fel d 1 monoclonal antibodies (REGN1908/1909) in preventing cat allergen-induced early asthmatic responses (EAR) in cat-allergic patients with mild asthma.
METHODS
Patients were randomized to single-dose REGN1908/1909 600 mg (n = 29) or placebo (n = 27). Forced expiratory volume in 1 second (FEV1) was measured for up to 4 hours in a cat allergen environmental exposure unit (EEU) up to 85 days after dosing. Assessments included between-group differences in change from baseline in FEV1 area under the curve (AUC; 0-2 hours) and incidence of EAR (FEV1 reduction ≥20%).
RESULTS
Single-dose REGN1908/1909 significantly prevented reductions in FEV1 on days 8, 29, 57, and 85. Most REGN1908/1909 patients did not have an EAR by 4 hours (last timepoint tested). In contrast, placebo-treated patients experienced ≥20% mean FEV1 reduction on days 8, 29, 57, and 85 post-dosing, with most experiencing an EAR within 1 hour. REGN1908/1909-treated patients tolerated 3-fold higher allergen quantities (P < .05 at all timepoints) versus placebo. REGN1908/1909 substantially reduced skin test reactivity to cat allergen versus placebo at all timepoints tested (nominal P < .001). REGN1908/1909 was generally well tolerated; no serious adverse events or deaths were reported.
CONCLUSION
Single-dose REGN1908/1909 significantly prevented reductions in FEV1 in cat-allergic patients with mild asthma upon cat-allergen EEU exposure at 8 days and up to 85 days post-dose.